LivaNova
LIVN Nasdaq· Health Care Equipment
Last close · Oct 23, 2026
$80.90
KIRA · Stoqly’s AI analyst, in plain words
- LivaNova had $1.4B of revenue in fiscal 2025, up 10.7% on the year before. Over five years, revenue changed +8.2% a year on average.
- Its operating margin was 14.4%, up 4.1 pts: of every 100 in sales, about 14 is left after running the business.
- LivaNova lost $243M in fiscal 2025.
- Free cash flow was $173M in fiscal 2025, 12.5% of revenue.
- LivaNova returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count fell 0.1%.
- LivaNova has $260M more cash than debt.
Market cap
$4.6B
P/E
23.9x
Revenue
$1.4B
Net income
−$243M
Free cash flow
$173M
Operating margin
14.4%
LivaNova in 30 seconds · fiscal 2025
Are sales growing?
+10.7%
Yes. Sales grew 10.7% last year.
Does it make a profit?
−17.5%
No. It lost money last year.
Does profit turn into cash?
12.5%
Yes. 12.5% of sales ends up as free cash.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
23.9x
One share costs 23.9 times its yearly profit per share. Typical for its sector: 28.4x.
What LivaNova does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- LivaNova PLC
- CIK
- 0001639691
LivaNova · LIVN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.0B | $1.0B | $1.2B | $1.3B | $1.4B |
| Revenue growth | 10.8% | −1.3% | 12.9% | 8.7% | 10.7% |
| Gross margin | 68.2% | 69.2% | 65.5% | 68.1% | 67.7% |
| Operating margin | −0.1% | −7.5% | −5.9% | 10.3% | 14.4% |
| Net income | −$136M | −$86.2M | $17.5M | $63.2M | −$243M |
| Net margin | −13.1% | −8.4% | 1.5% | 5.0% | −17.5% |
| Diluted EPS | −$2.68 | −$1.61 | $0.32 | $1.16 | −$4.45 |
| Cash | |||||
| Cash from operations | $103M | $69.9M | $74.9M | $183M | $254M |
| Capital expenditure | $25.5M | $26.5M | $35.0M | $47.1M | $81.0M |
| Free cash flow | $77.1M | $43.4M | $39.9M | $136M | $173M |
| FCF margin | 7.4% | 4.3% | 3.5% | 10.8% | 12.5% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share count change | 4.2% | 5.6% | 1.4% | 0.7% | −0.1% |
| Debt and strength | |||||
| Cash and short-term investments | $208M | $214M | $267M | $429M | $636M |
| Debt incl. finance leases | $237M | $539M | $586M | $627M | $376M |
| Shareholders' equity | $1.3B | $1.2B | $1.3B | $1.3B | $1.2B |
| Current ratio | 1.0x | 3.0x | 3.0x | 2.9x | 1.4x |
| Interest coverage | −0.0x | −1.6x | −1.2x | 2.1x | 4.1x |
| Returns and quality | |||||
| Return on capital | −0.0% | −4.3% | −3.5% | 5.9% | 12.8% |
| Return on equity | −11.3% | −6.9% | 1.4% | 4.9% | −19.2% |
| Piotroski F-score | 6 | 6 | 5 | 6 | 5 |
| Altman Z'' | 0.1 | 1.2 | 1.4 | 2.3 | 0.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.0M
3 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
LivaNova · LIVN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| LivaNova LIVN | $4.6B | 10.7% | 14.4% | 12.5% | 12.8% | 23.9x | 5 |
| CONMED CNMD | $1.5B | 5.2% | 7.5% | 11.0% | 3.7% | — | 6 |
| Penumbra PEN | $12.8B | 17.5% | 13.5% | 12.5% | 18.8% | 79.7x | 7 |
| Integra Lifesciences IART | $936M | 1.5% | −30.2% | −1.9% | −22.0% | 70.1x | 5 |
| Integer ITGR | $4.3B | 8.0% | 11.9% | 5.7% | 6.6% | 34.7x | 7 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $80.90 a share, the company is worth $4.6B: 23.9 times its earnings of the last four quarters.
LivaNova grew sales faster than 3 of its 4 similar companies. Its P/E is higher than 0 of 3.
Source: SEC EDGAR XBRL filings (CIK 0001639691). Data updated October 16, 2026. For information only — not investment advice. Check the original filings before relying on any figure.